Discontinuation of nucleoside/nucleoside analogues therapy in compensated patients with hepatitis B cirrhosis after HBsAg negative conversion
10.3760/cma.j.issn.1674-2397.2022.01.002
- VernacularTitle:核苷(酸)类似物治疗乙型肝炎肝硬化代偿期患者HBsAg消失后可考虑停药
- Author:
Haiyan LIU
1
;
Huazhong CHEN
;
Tongjing XING
;
Wenhui TU
;
Lingjun YING
;
Jiang FENG
;
Yongzhi TANG
Author Information
1. 绍兴文理学院医学院 312099
- Keywords:
Hepatitis B;
Compensatory stage of liver cirrhosis;
Nucleoside/nucleoside analogues;
Hepatitis B surface antigen disappearance;
Drug withdrawal;
Safety
- From:
Chinese Journal of Clinical Infectious Diseases
2022;15(1):16-20
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety of discontinuing nucleoside/nucleoside analogue (NAs) therapy in patients with compensated hepatitis B cirrhosis after HBsAg negative conversion.Methods:A total of 3 783 patients with hepatitis B cirrhosis in compensated stage were treated with NAs at Taizhou Hospital, Taizhou Municipal Hospital and Taizhou Enze Hospital from January 2008 to December 2020. The clinical data and laboratory tests results of 85 patients with HBsAg negative conversion were retrospectively analyzed, including 36 cases discontinued the drug, and 49 continued to use drug. Chi-square test and rank-sum test were used for data analysis.Results:During the 24 and 48 months of follow-up, the ALT levels were within the normal range in both groups. There were no significant differences in positive rates of anti-HBs and HBeAg ( χ2=0.75, 0.39 and 0.90, P=0.78 0.84 and 0.34; χ2=0.40, 0.00 and 0.00, P=0.84, 1.00 and 1.00) between two groups. After 48 months of follow-up, 2 cases of primary liver cancer occurred in the discontinuation group and no primary liver cancer occurred in the continuation group ( χ2=0.89, P=0.34). Throughout the follow-up, HBsAg remained negative and HBV DNA load was below the lower limit of detection in both groups. Conclusions:Discontinuation of NAs can be considered after the HBsAg negative conversion in patients with compensated hepatitis B cirrhosis.
